To determine whether increasing YAP activity can inhibit the growth of ER+ breast cancer cells, we took advantage of a pharmacological small molecule inhibitor, XMU-MP-1 (Supplementary Fig. 2a), which specifically inhibits the kinase activity of MST1/2, thereby promoting YAP nuclear localization and activation31. Here, YAP1 is linked to breast carcinoma.